(PCVX) Vaxcyte - Ratings and Ratios

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology company specializing in the development of conjugate and novel protein vaccines to address unmet needs in bacterial infectious diseases. The companys lead candidate, VAX-24, is a 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) designed to prevent invasive pneumococcal disease (IPD). This vaccine candidate is notable for its broader serotype coverage compared to existing PCVs, potentially offering enhanced protection against pneumococcal infections. VAX-24 is currently in Phase 2 clinical trials, with a focus on demonstrating its immunogenicity and safety.

Complementing VAX-24, Vaxcyte is advancing VAX-31, a 31-valent PCV, which is in preclinical development. This candidate aims to further expand serotype coverage, addressing a broader range of pneumococcal strains. The company also has VAX-A1, a conjugate vaccine targeting Group A Streptococcus (GAS), a major cause of infectious diseases worldwide. Additionally, Vaxcyte is developing VAX-PG, a novel protein vaccine for periodontitis, and VAX-GI, aimed at preventing shigellosis and dysentery caused by Shigella and enterotoxigenic Escherichia coli (ETEC).

Originally founded in 2013 as SutroVax, Inc., the company rebranded as Vaxcyte, Inc. in May 2020 to reflect its expanded focus on vaccine development. Headquartered in San Carlos, California, Vaxcyte operates in the biotechnology sector with a market capitalization of approximately $3.89 billion USD as of the latest data. The companys stock is listed on the NASDAQ exchange under the ticker symbol PCVX.

From a technical perspective, Vaxcytes stock has shown recent price fluctuations, with a last price of $32.92 and a 20-day average volume of 2,710,706 shares. The stocks short-term moving averages (SMA 20: $33.62, SMA 50: $58.74) indicate a recent downtrend, while the long-term SMA 200 ($85.09) reflects a steeper decline over the past year. The Average True Range (ATR) of $4.23 suggests moderate volatility in recent trading sessions.

On the fundamental side, Vaxcytes price-to-book (P/B) ratio of 1.25 indicates that the stock is trading near its book value. However, the return on equity (RoE) of -14.03% highlights the companys current operating losses, typical for a clinical-stage biotech firm. With no P/E or P/S ratios available due to the absence of earnings or sales, investors are likely focusing on the companys pipeline progress and long-term growth potential.